CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that its President and Chief Executive Officer, Chuck Wilson PhD, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 1:55 pm ET. The conference is being held August 15-16, 2017 at the Le Parker Meridien in New York.
About Unum Therapeutics
Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087 in combination with rituximab, an anti-CD20 antibody, is Unum’s most advanced product candidate, currently in Phase I clinical testing for the treatment of adult patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma. ACTR707, an optimized ACTR construct for development in both hematologic and solid tumors, is Unum’s second program to enter Phase I clinical testing in combination with rituximab in the same patient population. The Company anticipates that enrollment in this trial will begin in the second half of 2017. Unum is headquartered in Cambridge, MA. For more information, visit www.unumrx.com/.
